Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11664)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 7, 2023 (publication date) through May 20, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Wang LF, Chen PR, He SK, Duan SH, Zhang Y. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review. World J Gastroenterol 2023; 29(29): 4481-4498 [PMID: 37621757 DOI: 10.3748/wjg.v29.i29.4481] |
|
|
|
| All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. | |
| For: | Wang LF, Chen PR, He SK, Duan SH, Zhang Y. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review. World J Gastroenterol 2023; 29(29): 4481-4498 [PMID: 37621757 DOI: 10.3748/wjg.v29.i29.4481] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5190/full/v29/i29/4481.htm |
| Number | Citing Articles |
| 1 |
Julia López De-La-Cruz, Fernando Gomollón, Javier Louro, Juan López Pérez, María Mercedes Nocito Colon, Beatriz Gallego Llera, Sandra García-Mateo, Samuel J Martínez-Domínguez, María Concepción Aso Gonzalvo, Carla J Gargallo-Puyuelo. Impact of HLADQA1*05 and HLADQA1*03 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2025; 19(6) doi: 10.1093/ecco-jcc/jjae178
|
| 2 |
Ahmad K. Al-Jalehawi, Samer Imad Mohammed. Clinical use of tumor necrosis factor-alpha inhibitors in Iraq: a review of their documented efficacy, safety, and associated genetics. Review of Clinical Pharmacology and Pharmacokinetics - International Edition 2024; 38(3): 335 doi: 10.61873/SEZR6390
|
| 3 |
Cody S Howe, Marina Chulkina, Ryan Syrcle, Christina McAninch, Steven McAninch, Irina V Pinchuk, Ellen J Beswick. MK2 Inhibition in CD4+ T Cells Protects Against IFNγ and IL-17A, Chronic Inflammation, and Fibrosis in Inflammatory Bowel Disease Models. Inflammatory Bowel Diseases 2025; 31(6): 1664 doi: 10.1093/ibd/izaf026
|
| 4 |
José Luis Rueda García, Cristina Suárez-Ferrer, Clara Amiama Roig, Laura García Ramírez, Cristina García Rojas, Eduardo Martín-Arranz, Joaquín Poza Cordón, María Sánchez Azofra, Jesús Noci, Cristina Cubillo García, María Dolores Martín-Arranz. Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn’s Disease. Therapeutic Advances in Gastroenterology 2025; 18 doi: 10.1177/17562848251324226
|
| 5 |
Yue Yang, Kan-Zuo Fu, Gu Pan. Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis. World Journal of Gastrointestinal Surgery 2024; 16(1): 228-238 doi: 10.4240/wjgs.v16.i1.228
Abstract(775) |
Core Tip(774) |
Full Article(HTML)(2733)
|
Full Article with Cover (PDF)-3312K(190)
|
Full Article (Word)-1272K(44)
|
Audio-338K(26)
|
Peer-Review Report-177K(139)
|
Answering Reviewers-115K(126)
|
Supplementary Material-213K(128)
|
Full Article (PDF)-3033K(218)
|
Full Article (XML)-117K(133)
|
Times Cited (12)
|
Total Visits (9619)
|
Open
|
| 6 |
Isabelle Whittle, Eva Brown Hajdukova, Hannah Coles, Natasha Perry, Lisa Perrett, Richard Perry, Kyran Jones. Understanding Patient Preferences on Inflammatory Bowel Disease Treatment Modalities and Outcomes: A Global Targeted Literature Review. Advances in Therapy 2026; doi: 10.1007/s12325-026-03565-9
|
| 7 |
Qinhui Tang, Xiaowei Tang, Wenmeng Yin, Yantong Li, Xiaolin Zhong, Vinay Kumar. Infective pneumonia following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database. PLOS One 2025; 20(8): e0317242 doi: 10.1371/journal.pone.0317242
|
| 8 |
Ji-Eun Na, Yong-Eun Park, Jong-Ha Park, Tae-Oh Kim, Jong-Yoon Lee, Jong-Hoon Lee, Su-Bum Park, Seung-Bum Lee, Seung-Min Hong. Efficacy of Second-Line Biological Therapies in Moderate to Severe Ulcerative Colitis Patients with Prior Failure of Anti-Tumor Necrosis Factor Therapy: A Multi-Center Study. Journal of Personalized Medicine 2024; 14(10): 1066 doi: 10.3390/jpm14101066
|
| 9 |
Xiaoyu Cai, Yao Yao, Yongquan Zheng, Xuezhi Zhao. Multi-omics gut microbiome signatures for treat-to-target management in inflammatory bowel disease. Microbiological Research 2026; 309: 128511 doi: 10.1016/j.micres.2026.128511
|
| 10 |
M. Hupé, A. Abdelmoula, T. Chateau, S. Pestour, X. Roblin, C. Gay, G. Boschetti, S. Nancey, N. Mathieu. Impact of immediate drug optimization of ustekinumab on medium term targets in Crohn’s disease: results from the multicentre retrospective real-life study MUST. Digestive and Liver Disease 2025; 57(9): 1772 doi: 10.1016/j.dld.2025.05.024
|
| 11 |
Nikil Vootukuru, Abhinav Vasudevan. Approach to loss of response to advanced therapies in inflammatory bowel disease. World Journal of Gastroenterology 2024; 30(22): 2902-2919 doi: 10.3748/wjg.v30.i22.2902
|
| 12 |
Shi-Yan Zhang. Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations. World Journal of Gastroenterology 2024; 30(41): 4411-4416 doi: 10.3748/wjg.v30.i41.4411
|
| 13 |
Junya Shiota, Moto Kitayama, Hiroko Inomata, Taro Akashi, Maiko Tabuchi, Keiichi Hashiguchi, Kayoko Matsushima, Yuko Akazawa, Naoyuki Yamaguchi, Hisamitsu Miyaaki. Upadacitinib Treatment Outcomes in Crohn’s Disease: A Retrospective Analysis of Clinical Response and Perianal Fistula Resolution. Inflammatory Intestinal Diseases 2026; 11(1): 100 doi: 10.1159/000550543
|
| 14 |
Chun-xiu Xiao, Wen-yuan Wu, Shi-cong Li, Mei-ling Dong, Yu-hang Bian, Meng Yu, Xiang Lv, Wei-guo Chen, Min Hong, Jing Zhou, Yang Sun, Hong-yue Ma, Yu-yu Zhu. 5-OH-TMT mitigates colitis through HTRA2 binding–mediated activation of the Dectin-1 signaling pathway. Acta Pharmacologica Sinica 2026; doi: 10.1038/s41401-026-01782-0
|
| 15 |
Simona Grad, Radu A. Farcas, Dan L. Dumitrascu, Teodora Surdea-Blaga, Abdulrahman Ismaiel, Stefan Popa. Predictors of Immunogenicity and Loss of Response to ANTI-TNFα Therapy in Crohn Disease—A Systematic Review. American Journal of Therapeutics 2025; 32(3): e262 doi: 10.1097/MJT.0000000000001867
|
| 16 |
Moushira Zaki, Hisham A. Orban, Marwa Mahmoud, Eman R. Youness, Hoda F. Booles, Wagdy K. B. Khalil, Wafaa Wafy, Kamal A. El-Atrebi, Khaled Hamed, Hala T. El-Bassyouni. Evaluation of adropin, fibroblast growth factor-1 (FGF-1), and Toll-like receptor-1 (TLR1) biomarkers in patients with inflammatory bowel disease: gene expression of TNF-α as a marker of disease severity. Egyptian Journal of Medical Human Genetics 2024; 25(1) doi: 10.1186/s43042-024-00533-2
|
| 17 |
Xin Gao, Cui Zhang, Zeman Zhao, Yujie Chen, Hehua Lei, Zheng Cao, Wenkai Yu, Weichuan Lin, Yanmeng He, Xinzhi Li, Qingwei Xiang, Zhiwen Zhang, Limin Zhang, Gang Chen. Ophiopogon japonicus Polysaccharides Promote Microbial Production Of Chenodeoxycholic Acid To Alleviate Ulcerative Colitis in Mice by Inhibiting the STING1-Related NF-κB Pathway. Journal of Agricultural and Food Chemistry 2026; 74(15): 12087 doi: 10.1021/acs.jafc.5c14733
|
| 18 |
Yi-mei Chen, Qi-wen Xiao, Yong-jie Shi, Shao-na Zeng, Hong-yun Jia, Xun Zheng, Si-cong Huang. Targeting IRF5 enhances S100A9-mediated granulocytic MDSC accumulation and suppressive function: a novel therapeutic strategy for ulcerative colitis. International Immunopharmacology 2026; 181: 116733 doi: 10.1016/j.intimp.2026.116733
|
| 19 |
Maximilian Berlet, Kamacay Cira, Alissa Jell, Christian Stoess, Helmut Friess, Dirk Wilhelm, Daniel Reim, Marie-Christin Weber, Philipp-Alexander Neumann. Trends in surgical treatment for ulcerative colitis in the era of biologics – A population-based study using German diagnosis-related groups data. Surgery 2025; 185: 109511 doi: 10.1016/j.surg.2025.109511
|
| 20 |
Hannah Cruz, Prarthna Shah, Nicholas Wohlgemuth, Robert Ketchum, Imad Nassif, Chien-An A. Hu. Pyroptosis in ulcerative colitis: biomarkers and therapeutic targets. Journal of Biomedical Science 2025; 32(1) doi: 10.1186/s12929-025-01206-x
|
| 21 |
Juan Sebastián Frías Ordoñez, Luis Jorge Lombana Amaya, Hernando Marulanda Fernandez, William Otero-Regino. Inhibidores del factor de necrosis tumoral y riesgo de cáncer anorrectal en pacientes con enfermedad inflamatoria intestinal: ¿es acaso una relación constante y peligrosa?. Revista colombiana de Gastroenterología 2026; 41(1): 51 doi: 10.22516/25007440.1303
|
| 22 |
Dongyuan Zheng, Qinke Xu, Jin Wu, Zhouyue Gu, Jieya Chen, Yingchao Liu. Prevalence and bidirectional association between primary sclerosing cholangitis and Crohn's disease: A systematic review and meta-analysis. Gastroenterología y Hepatología (English Edition) 2025; 48(8): 502346 doi: 10.1016/j.gastre.2025.502346
|
| 23 |
Konstantinos C. Mpakogiannis, Paraskevi Chasani, Ioanna Nefeli Mastorogianni, Konstantinos H. Katsanos, Fotios S. Fousekis. Predictors of First Anti-TNF Treatment Failure in Patients with Inflammatory Bowel Disease: A Single-Center Cohort Study. Biomedicines 2026; 14(5): 984 doi: 10.3390/biomedicines14050984
|
| 24 |
Dongyuan Zheng, Qinke Xu, Jin Wu, Zhouyue Gu, Jieya Chen, Yingchao Liu. Prevalence and bidirectional association between primary sclerosing cholangitis and Crohn's disease: A systematic review and meta-analysis. Gastroenterología y Hepatología 2025; 48(8): 502346 doi: 10.1016/j.gastrohep.2025.502346
|